肾细胞癌围术期免疫治疗现况

Current status of perioperative immunotherapy for renal cell carcinoma

肾细胞癌(renal cell carcinoma,RCC)作为泌尿系统常见肿瘤之一,近年来免疫治疗方案的涌现极大改善了转移性RCC患者的生存预后。但对于早期RCC,仍有较多患者出现术后肿瘤复发,故探索RCC围术期治疗模式具有迫切的现实意义。目前,评估免疫治疗对围术期RCC患者生存获益的临床研究陆续开展,这些临床研究的开展将探索RCC最佳围术期治疗方案和模式,有助于明确高复发风险患者,寻找RCC围术期治疗的最佳获益人群。这些前瞻性研究也将有望优化RCC患者的围术期治疗,为今后临床治疗提供重要依据。

Renal cell carcinoma(RCC)is one of the common tumors of the urinary system.In recent years,the emergence of immunotherapy has greatly improved the prognosis of patients with metastatic RCC.However,for early-stage renal cancer carcinoma,there are a considerable number of patients still experience tumor recurrence after surgery.Therefore,exploring treatment modalities for RCC in perioperative period is of urgent practical significance.Currently,clinical studies evaluating the survival benefits of immunotherapy for patients with RCC in perioperative period are being conducted one after another.These clinical studies will explore the optimal perioperative treatment regimens and modalities for RCC,helping to identify patients at high risk of recurrence and identify the ideal beneficiaries of perioperative treatment for RCC.These prospective studies are also expected to optimize the perioperative treatment of RCC patients and become important evidence for guiding clinical practice in the future.